Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Movement Disorders

• Publication date

  2003-09-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1002/mds.10566PMID 14502659
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop

  2006cited by this paper
• Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: A cross‐sectional comparative study

  2003cited by this paper
• Dramatic response to chemotherapy in oligodendroglial gliomatosis cerebri

  2003cited by this paper
• Beyond the iron mask: Towards better recognition and treatment of depression associated with Parkinson's disease

  2002cited by this paper
• Rivastigmine for the Treatment of Dementia and Visual Hallucinations Associated with Parkinson's Disease: A Case Series

  2002cited by this paper
• Fluctuations in attention

  2002cited by this paper
• Successful Use of Donepezil for the Treatment of Psychotic Symptoms in Patients With Parkinson's Disease

  2002cited by this paper
• Drugs to treat dementia and psychosis: management of Parkinson's disease.

  2002cited by this paper
• Genomics and dementia--new drug targets ahead?

  2002cited by this paper
• Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action.

  2002cited by this paper
• Do cholinesterase inhibitors slow progression of Alzheimer's disease?

  2002cited by this paper
• Drugs to treat dementia and psychosis

  2002cited by this paper
• Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain.

  2002cited by this paper
• Effects of Rivastigmine on Cognitive Function in Dementia with Lewy Bodies: A Randomised Placebo-Controlled International Study Using the Cognitive Drug Research Computerised Assessment System

  2002cited by this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase Inhibitors

  2002cited by this paper
• Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study

  2002cited by this paper
• Incidence and prediction of falls in Parkinson's disease: a prospective multidisciplinary study

  2002cited by this paper
• Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response.

  2002cited by this paper
• The association of incident dementia with mortality in PD

  2002cited by this paper
• Parkinson's disease and dementia with Lewy bodies: One disease or two?

  2002cited by this paper
• Combined effect of age and severity on the risk of dementia in Parkinson's disease

  2002cited by this paper
• Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease

  2002cited by this paper
• Cognitive impairments in advanced PD without dementia

  2002cited by this paper
• The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer's disease

  2001cited by this paper
• Long-Term Use of Rivastigmine in Patients With Dementia With Lewy Bodies: An Open-Label Trial

  2001cited by this paper
• Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial

  2001cited by this paper
• Visual hallucinations are associated with lower alpha bungarotoxin binding in dementia with Lewy bodies.

  2001cited by this paper
• Synucleinopathies: clinical and pathological implications.

  2001cited by this paper
• Comparison of extrapyramidal signs in dementia with Lewy bodies and Parkinson's disease.

  2001cited by this paper
• Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: A two‐year follow‐up study of previously untreated patients

  2000cited by this paper
• Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia.

  2000cited by this paper
• What contributes to quality of life in patients with Parkinson's disease?

  2000cited by this paper
• A review of the cognitive and behavioral symptoms in dementia with Lewy bodies.

  2000cited by this paper
• Motor impairment in PD

  2000cited by this paper
• Dementia with Lewy bodies: findings from an international multicentre study

  2000cited by this paper
• Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.

  2000cited by this paper
• Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study

  2000cited by this paper
• Delusions associated with elevated muscarinic binding in dementia with Lewy bodies

  2000cited by this paper
• Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson’s disease

  2000cited by this paper
• The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia

  2000cited by this paper
• Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study.

  2000cited by this paper
• Atypical antipsychotics in the treatment of drug‐induced psychosis in Parkinson's disease

  2000cited by this paper
• Predictors of Nursing Home Placement in Parkinson's Disease: A Population‐Based, Prospective Study

  2000cited by this paper
• Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial

  2000cited by this paper
• Cholinergic dysfunction in diseases with Lewy bodies

  2000cited by this paper
• Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study.

  1999cited by this paper
• The Prevalence, Assessment and Associations of Falls in Dementia with Lewy Bodies and Alzheimer’s Disease

  1999cited by this paper
• Mental symptoms in Parkinson's disease are important contributors to caregiver distress

  1999cited by this paper
• Olanzapine in dementia with Lewy bodies: a clinical study

  1999cited by this paper
• Selectivity of Cholinesterase Inhibition

  1999cited by this paper
• Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.

  1999cited by this paper
• Report of the second dementia with Lewy body international workshop

  1999cited by this paper
• REM sleep behavior disorder and degenerative dementia

  1998cited by this paper
• Neuroleptic sensitivity to clozapine in dementia with Lewy bodies.

  1998cited by this paper
• Donepezil for Treatment of Dementia With Lewy Bodies: A Case Series of Nine Patients

  1998cited by this paper
• Butyrylcholinesterase K: an association with dementia with Lewy bodies.

  1998cited by this paper
• Dementia with Lewy Bodies Versus Pure Alzheimer Disease: Differences in Cognition, Neuropathology, Cholinergic Dysfunction, and Synapse Density

  1997cited by this paper
• A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients

  1997cited by this paper
• Neuropsychological performance in Lewy body dementia and Alzheimer's disease

  1997cited by this paper
• Longus cervicis colli "myositis" (syn: retropharyngeal tendinitis)

  1996cited by this paper
• Cholinesterase inhibition in Parkinson's disease.

  1996cited by this paper
• In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease

  1996cited by this paper
• Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB)

  1996cited by this paper
• Neuroleptic sensitivity to risperidone in Lewy body dementia.

  1995cited by this paper
• Lewy Body Dementia – Diagnosis and Treatment

  1995cited by this paper
• The Neuropsychiatric Inventory

  1994cited by this paper
• Risk factors for nursing home placement in advanced Parkinson's disease

  1993cited by this paper
• Alterations in striatal and extrastriatal D‐1 and D‐2 dopamine receptors in the MPTP‐treated common marmoset: An autoradiographic study

  1993cited by this paper
• Exacerbation of parkinsonism by tacrine.

  1992cited by this paper
• Operational criteria for senile dementia of Lewy body type (SDLT)

  1992cited by this paper
• Neuroleptic sensitivity in patients with senile dementia of Lewy body type.

  1992cited by this paper
• Evidence of a Monoaminergic‐Cholinergic Imbalance Related to Visual Hallucinations in Lewy Body Dementia

  1990cited by this paper
• A current analysis of behavioral problems in patients with idiopathic Parkinson's disease

  1989cited by this paper

• α-Synuclein conformers reveal link to clinical heterogeneity of α-synucleinopathies

  2023cites this paper
• Clinical implications for dopaminergic and functional neuroimage research in cognitive symptoms of Parkinson’s disease

  2021cites this paper
• CIA_A_264688 1841..1862

  2020cites this paper
• Activities of Daily Living and Associated Costs in the Most Widespread Neurodegenerative Diseases: A Systematic Review

  2020cites this paper
• Seeding and structural varibility in α-synucleinopathies

  2019cites this paper
• Targeting alpha synuclein and amyloid beta by a multifunctional, brain-penetrant dopamine D2/D3 agonist D-520: Potential therapeutic application in Parkinson’s disease with dementia

  2019cites this paper
• The Neuropsychological Profile of Mild Cognitive Impairment in Lewy Body Dementias

  2019cites this paper
• UvA-DARE ( Digital Academic Repository ) Cholinergic deficiency and inflammation in cognitive dysfunction

  2017cites this paper
• Dementia With Lew Body

  2016cites this paper
• Presence or absence of cognitive complaints in Parkinson’s disease: mood disorder or anosognosia?

  2015cites this paper
• Liquormarker in der Diagnostik bei Patienten mit Morbus Parkinson, Parkinson-Demenz-Komplex und

  2015cites this paper
• Dementia – The real problem for patients with Parkinson's disease

  2014cites this paper
• SPECT/PET Findings in Lewy Body Dementia

  2014cites this paper
• Psychiatric Disturbances of Attention

  2014cites this paper
• Diffusion Tensor Imaging Reveals White Matter Changes Associated With Cognitive Status in Patients With Parkinson’s Disease

  2013influential citation
• With Parkinson ' s Disease Diffusion Tensor Imaging Reveals White Matter Changes Associated With Cognitive Status in Patients

  2013influential citation
• Association of a polymorphism in mitochondrial transcription factor A (TFAM) with Parkinson's disease dementia but not dementia with Lewy bodies.

  2013cites this paper
• Motor and non-motor features of Parkinson's disease - a review of clinical and experimental studies.

  2012cites this paper
• Lewy Body Dementia

  2012cites this paper
• Donepezil in Parkinson's disease dementia: A randomized, double‐blind efficacy and safety study

  2012cites this paper
• Clinical Validity of the Mattis Dementia Rating Scale-2 in Parkinson Disease With MCI and Dementia

  2012cites this paper
• Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.

  2012cites this paper
• Parkinson's Disease Dementia and Potential Therapeutic Strategies

  2011cites this paper
• Psychiatric symptoms in dementia with Lewy Bodies: Diagnostic and management issues

  2011cites this paper
• Dementia in Parkinson's Disease: A Clinical Review

  2011cites this paper
• Neurotransmission in Parkinson’s disease: beyond dopamine

  2010cites this paper
• Rivastigmine in Parkinson's disease dementia

  2009cites this paper
• Lewy body dementia.

  2009cites this paper
• Clinical measures of progression in Parkinson's disease

  2009cites this paper
• Cognitive Characteristics Associated with Mild Cognitive Impairment in Parkinson’s Disease

  2009cites this paper
• UvA-DARE ( Digital Academic Repository ) Cholinergic deficiency and inflammation in cognitive dysfunction

  2008cites this paper
• [Dementia in Parkinson's disease].

  2008cites this paper
• The Characteristics of Cognitive Impairment in Parkinson’s Disease and Recognition of Cognitive Symptom by Questionnaire

  2008cites this paper
• Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies

  2008cites this paper
• Effect of thalamotomy on focal hand dystonia in a family with DYT1 mutation

  2008cites this paper
• Rivastigmine in Parkinson’s disease dementia

  2008cites this paper
• Clinical aspects of dementia with Lewy bodies.

  2008cites this paper
• Diagnosis and management of Parkinson's disease dementia

  2008cites this paper
• Cholinergic deficiency and inflammation in cognitive dysfunction

  2008cites this paper
• Drug Profi le Rivastigmine in Parkinson ’ s disease dementia

  2008cites this paper
• Medications That Exacerbate or Induce Cognitive-Communication Deficits

  2008cites this paper
• Demência na doença de Parkinson Dementia in Parkinson's disease

  2008cites this paper
• Rivastigmine in Parkinson's disease dementia: profile report.

  2007cites this paper
• Links Between Amyloid and Tau Biology in Alzheimer’s Disease and Their Cholinergic Aspects

  2007cites this paper
• DLB and PDD boundary issues

  2007cites this paper
• Cognitive Impairment in Parkinson’s Disease and Dementia with Lewy Bodies: A Spectrum of Disease

  2007cites this paper
• MRI confirms mild cognitive impairments prodromal for Alzheimer's, vascular and Parkinson-Lewy body dementias.

  2007cites this paper
• An Investigation of the Cognitive and Psychiatric Profile for People with Parkinson's Disease Without Dementia.

  2007cites this paper
• Demenza a corpi di Lewy

  2007cites this paper
• Démence à corps de Lewy

  2007cites this paper
• Dopaminergic Agonists: Possible Neurorescue Drugs Endowed with Independent and Synergistic Multisites of Action

  2007cites this paper
• biomarkers DLB and PDD boundary issues: Diagnosis, treatment, molecular pathology, and

  2007cites this paper
• Palliative Care in Amyotrophic Lateral Sclerosis, Parkinson's Disease, and Multiple Sclerosis

  2007cites this paper
• Delusion and Hallucination in Parkinson's Disease: A Pilot Study of Clinical Features and Pathogenesis

  2007cites this paper
• The management of psychosis in movement disorder patients

  2007cites this paper
• Non-motor dysfunction in Parkinson's disease.

  2007cites this paper
• The use of EEG in the diagnosis of dementia with Lewy bodies

  2007cites this paper
• White matter hyperintensities and cortical acetylcholinesterase activity in parkinsonian dementia

  2006cites this paper
• Cognitive, affective, and psychiatric features of Parkinson's disease.

  2006cites this paper
• Dementia with Lewy bodies: an emerging disease.

  2006cites this paper
• Depression in Parkinson's disease – a review

  2006cites this paper
• Cholinesterase inhibitors for Parkinson's disease dementia.

  2006cites this paper
• Depression in Parkinson Disease

  2006cites this paper
• Rivastigmine

  2006cites this paper
• Clinical management of Parkinson’s disease dementia: pitfalls and progress

  2006cites this paper
• Otępienie z ciałami Lewy’ego – nowe kryteria diagnostyczne i postępowanie terapeutyczne

  2006cites this paper
• Dementia secondary to Parkinson's disease versus dementia with Lewy bodies

  2005cites this paper
• Psychosis in Parkinson’s disease

  2005cites this paper
• A review of studies describing the use of acetyl cholinesterase inhibitors in Parkinson's disease dementia

  2005cites this paper
• Movement Disorders: Overview and Treatment Options

  2005cites this paper
• Idiopathisches Parkinson-Syndrom und andere Basalganglienerkrankungen

  2005cites this paper
• The treatment of dementia with Lewy bodies

  2005cites this paper
• What's new in… Psychiatry: dementia with Lewy bodies

  2004cites this paper
• Evidence for Impaired Encoding and Retrieval Memory Profiles in Parkinson Disease

  2004influential citation
• Dementia with Lewy Bodies: Implications for Clinical Trials

  2004influential citation
• Parkinson's disease

  2004cites this paper
• Dementia in Parkinson's disease: cause and treatment

  2004cites this paper
• Psychotic symptoms in Parkinson’s disease: pathophysiology and management

  2004cites this paper
• Psychotic symptoms in Parkinson's disease: pathophysiology and management.

  2004cites this paper
• Dementia with Lewy bodies

  2004cites this paper
• Are Parkinson’s Disease with dementia and Dementia with lewy Bodies the Same Entity?

  2004cites this paper
• Cognitive dysfunction and dementia in Parkinson’s disease

  2004cites this paper
• Cognitive issues in Parkinson's disease.

  2004cites this paper
• Impact of genetic analysis on Parkinson's disease research

  2003cites this paper
• This Work Is Licensed under a Creative Commons Attribution 4.0 International License Date Deposited: Neurophysiological Biomarkers for Lewy Body Dementias

  year unknowncites this paper